[
  {
    "ts": "2025-09-23T23:02:18+00:00",
    "headline": "Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment",
    "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Bristol-Myers Squibb Company is placed third among them. Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical leader in oncology, immunology, cardiovascular disease, and fibrosis, is undergoing major strategic changes as it adapts to shifting market conditions. […]",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-230218670.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "756c7f13-666d-3fa5-9594-0fe27fe64bc9",
      "content": {
        "id": "756c7f13-666d-3fa5-9594-0fe27fe64bc9",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment",
        "description": "",
        "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Bristol-Myers Squibb Company is placed third among them. Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical leader in oncology, immunology, cardiovascular disease, and fibrosis, is undergoing major strategic changes as it adapts to shifting market conditions. […]",
        "pubDate": "2025-09-23T23:02:18Z",
        "displayTime": "2025-09-23T23:02:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1f6bf11ec73fb18d603d5489db1ef2d2",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UX8ydRj5rQeMKOlWRwu0Mg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1f6bf11ec73fb18d603d5489db1ef2d2.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MdcJ93x.llnj2Wn.muBKFw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1f6bf11ec73fb18d603d5489db1ef2d2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-230218670.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-230218670.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-23T11:41:00+00:00",
    "headline": "Bristol Myers says next-gen blood cancer drug hits goal in key study",
    "summary": "The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster Revlimid franchise.",
    "url": "https://www.biopharmadive.com/news/bristol-myers-iberdomide-multiple-myeloma-study-results-excaliber/760845/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "f7587be9-337f-3148-96fd-b600746178e0",
      "content": {
        "id": "f7587be9-337f-3148-96fd-b600746178e0",
        "contentType": "STORY",
        "title": "Bristol Myers says next-gen blood cancer drug hits goal in key study",
        "description": "",
        "summary": "The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster Revlimid franchise.",
        "pubDate": "2025-09-23T11:41:00Z",
        "displayTime": "2025-09-23T11:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/30754989c2b465b1baaa8a9b439e552c",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "A micrograph of myeloma neoplasm in a bone marrow biopsy.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9_P97Fu.XEYEvtEuni5gOg--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/30754989c2b465b1baaa8a9b439e552c.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PFWML9iN01URa3WbA9kYMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/30754989c2b465b1baaa8a9b439e552c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/bristol-myers-iberdomide-multiple-myeloma-study-results-excaliber/760845/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-says-next-gen-114100726.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-23T10:59:00+00:00",
    "headline": "Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma",
    "summary": "PRINCETON, N.J., September 23, 2025--Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-announces-phase-105900609.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "9685ebd2-c632-3e28-88ed-7fa4e2648a34",
      "content": {
        "id": "9685ebd2-c632-3e28-88ed-7fa4e2648a34",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma",
        "description": "",
        "summary": "PRINCETON, N.J., September 23, 2025--Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies",
        "pubDate": "2025-09-23T10:59:00Z",
        "displayTime": "2025-09-23T10:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a2853fea4657d4cd3d3d9efa3599b3f0",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3_9bXXKXfLkoWyp_u9DuBA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a2853fea4657d4cd3d3d9efa3599b3f0.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NttUH3Knm14qXIVUfN4o_g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a2853fea4657d4cd3d3d9efa3599b3f0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-announces-phase-105900609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-announces-phase-105900609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-23T09:20:00+00:00",
    "headline": "Bull of the Day: Halozyme Therapeutics (HALO)",
    "summary": "The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth",
    "url": "https://finance.yahoo.com/news/bull-day-halozyme-therapeutics-halo-092000468.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9fa81617-9d8a-338b-8892-eba12de41219",
      "content": {
        "id": "9fa81617-9d8a-338b-8892-eba12de41219",
        "contentType": "STORY",
        "title": "Bull of the Day: Halozyme Therapeutics (HALO)",
        "description": "",
        "summary": "The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth",
        "pubDate": "2025-09-23T09:20:00Z",
        "displayTime": "2025-09-23T09:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/73810014b308f0729989eeb0f5114157",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HnFHpIz.hMZ47girE6zF4w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/73810014b308f0729989eeb0f5114157.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QO6i8VfrsJX1wwm2jssu5g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/73810014b308f0729989eeb0f5114157.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-day-halozyme-therapeutics-halo-092000468.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-day-halozyme-therapeutics-halo-092000468.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HALO"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-23T07:26:00+00:00",
    "headline": "1 Reason to Buy Bristol Myers Squibb Stock",
    "summary": "Find out why investors seeking passive income want shares of this dividend payer in their portfolio.",
    "url": "https://www.fool.com/investing/2025/09/23/1-reason-to-buy-bristol-myers-squibb-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "92b09cf6-6e31-3740-a4d2-48adde27b028",
      "content": {
        "id": "92b09cf6-6e31-3740-a4d2-48adde27b028",
        "contentType": "STORY",
        "title": "1 Reason to Buy Bristol Myers Squibb Stock",
        "description": "",
        "summary": "Find out why investors seeking passive income want shares of this dividend payer in their portfolio.",
        "pubDate": "2025-09-23T07:26:00Z",
        "displayTime": "2025-09-23T07:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/6603e16fcb13a5dbc4111896cd228891",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Highly engaged investor with multiple screens.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hf3MLDjJbsjPv7oeOzAfvQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/6603e16fcb13a5dbc4111896cd228891.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ca4.MV5u38m5aa9OxO5nEw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/6603e16fcb13a5dbc4111896cd228891.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/09/23/1-reason-to-buy-bristol-myers-squibb-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-reason-buy-bristol-myers-072600131.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]